Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1998

View Archived Issues

Company Profile: Millennium

Clinical development of LM-AS-013 advances at Green Cross

Inhibitors of the production or release of sCD23, TNF

Dopamine D4 receptor antagonists for imaging and therapy disclosed by Janssen

New excitatory amino acid antagonists in development at Pfizer

Meiji Seika describes 5-HT3 partial agonists for GI disorders

Triangle reports results from phase I/II FTC trial

Tsumura team reveals semisynthetic huperzine derivatives

More new agents for influenza from Lilly

PMPA reduces viral load in phase I/II

Potent, orally active inhibitor of kynurenine 3-hydroxylase discovered at Roche

Diphenylalkylamine derivative with cardioprotective properties characterized

ArQule and CuraGen establish broad drug discovery collaboration

Comparative trial of intracavernous alprostadil and MUSE for ED

Swiss Remune trials initiated

Long-term efficacy of epoprostenol for primary pulmonary hypertension

Optison imaging agent launched in U.S.

FDA advisory committee recommends Integrilin approval

Hybridon antitumor antisense compound enters clinical trials

Folic acid therapy and cardiovascular risk reduction

Anesta signs European marketing agreement for Actiq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...